{"transactions":[{"id":1479822,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2024-06-14T20:18:57.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":49933,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."}],"balance_after":49933,"derivative":{"exercise_price":6.3,"exercise_date":"2025-06-12","expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":49933},"source":{"system":"sec-edgar","filing":"0001127602-24-018705","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224018705/form4.xml","form_type":"4"}},{"id":1479821,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-14T20:18:57.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":6820,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the \"Director Compensation Policy\"), which will vest on the first anniversary of the date of grant."}],"balance_after":36431,"source":{"system":"sec-edgar","filing":"0001127602-24-018705","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760224018705/form4.xml","form_type":"4"}},{"id":1855052,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2023-06-15T20:28:04.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":39072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."}],"balance_after":39072,"derivative":{"exercise_price":8.18,"exercise_date":"2024-06-13","expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":39072},"source":{"system":"sec-edgar","filing":"0001127602-23-018765","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223018765/form4.xml","form_type":"4"}},{"id":1855051,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-15T20:28:04.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":16745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the \"Director Compensation Policy\"), which will vest on the first anniversary of the date of grant."}],"balance_after":29611,"source":{"system":"sec-edgar","filing":"0001127602-23-018765","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760223018765/form4.xml","form_type":"4"}},{"id":2238279,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2022-06-09T20:43:10.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":30022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy."}],"balance_after":30022,"derivative":{"exercise_price":10.79,"exercise_date":"2023-06-07","expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":30022},"source":{"system":"sec-edgar","filing":"0001127602-22-017153","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222017153/form4.xml","form_type":"4"}},{"id":2238278,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-06-09T20:43:10.000Z","date":"2022-06-07","kind":"grant","acquired":true,"shares":12866,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the \"Director Compensation Policy\"), which will vest on the first anniversary of the date of grant."}],"balance_after":12866,"source":{"system":"sec-edgar","filing":"0001127602-22-017153","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222017153/form4.xml","form_type":"4"}},{"id":2294269,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2022-04-20T20:23:20.000Z","date":"2022-04-18","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vested 1/12 per month for a period of 12 months, beginning on June 23, 2012."}],"balance_after":0,"derivative":{"exercise_price":3.32,"expiration_date":"2022-05-23","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-22-012272","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222012272/form4.xml","form_type":"4"}},{"id":2294268,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-04-20T20:23:20.000Z","date":"2022-04-18","kind":"sale","acquired":false,"shares":5000,"price":11.04,"value":55200.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001127602-22-012272","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222012272/form4.xml","form_type":"4"}},{"id":2294267,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-04-20T20:23:20.000Z","date":"2022-04-18","kind":"exercise","acquired":true,"shares":5000,"price":3.32,"value":16600.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001127602-22-012272","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222012272/form4.xml","form_type":"4"}},{"id":2392863,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2022-02-16T21:25:40.000Z","date":"2022-02-15","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 1/12 per month for a period of 12 months, beginning on June 23, 2012."}],"balance_after":5000,"derivative":{"exercise_price":3.32,"expiration_date":"2022-05-23","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-22-005295","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222005295/form4.xml","form_type":"4"}},{"id":2392862,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-02-16T21:25:40.000Z","date":"2022-02-15","kind":"sale","acquired":false,"shares":5000,"price":18.5,"value":92500.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.00 to $18.76. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001127602-22-005295","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222005295/form4.xml","form_type":"4"}},{"id":2392861,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-02-16T21:25:40.000Z","date":"2022-02-15","kind":"exercise","acquired":true,"shares":5000,"price":3.32,"value":16600.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001127602-22-005295","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760222005295/form4.xml","form_type":"4"}},{"id":2508923,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2021-11-17T21:27:57.000Z","date":"2021-11-15","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 1/12 per month for a period of 12 months, beginning on June 23, 2012."}],"balance_after":10000,"derivative":{"exercise_price":3.32,"expiration_date":"2022-05-23","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-21-029440","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221029440/form4.xml","form_type":"4"}},{"id":2508922,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-11-17T21:27:57.000Z","date":"2021-11-15","kind":"sale","acquired":false,"shares":5000,"price":12.27,"value":61350.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.22 to $12.29. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001127602-21-029440","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221029440/form4.xml","form_type":"4"}},{"id":2508921,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-11-17T21:27:57.000Z","date":"2021-11-15","kind":"exercise","acquired":true,"shares":5000,"price":3.32,"value":16600.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001127602-21-029440","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221029440/form4.xml","form_type":"4"}},{"id":2566808,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Non-Qualified Stock Option","published_at":"2021-09-17T20:31:32.000Z","date":"2021-09-15","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 1/8 per month for a period of 8 months, beginning on October 10, 2011."}],"balance_after":0,"derivative":{"exercise_price":2.63,"expiration_date":"2021-10-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-21-025496","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221025496/form4.xml","form_type":"4"}},{"id":2566807,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-09-17T20:31:32.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":5000,"price":15.06,"value":75300.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $14.90 to $15.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001127602-21-025496","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221025496/form4.xml","form_type":"4"}},{"id":2566806,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-09-17T20:31:32.000Z","date":"2021-09-15","kind":"exercise","acquired":true,"shares":5000,"price":2.63,"value":13150.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001127602-21-025496","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221025496/form4.xml","form_type":"4"}},{"id":2571431,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2021-09-14T20:14:23.000Z","date":"2021-09-10","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":2.91,"exercise_date":"2020-05-29","expiration_date":"2029-05-29","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001127602-21-025252","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221025252/form4.xml","form_type":"4"}},{"id":2571430,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2021-09-14T20:14:23.000Z","date":"2021-09-10","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.22,"exercise_date":"2016-06-23","expiration_date":"2026-05-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001127602-21-025252","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221025252/form4.xml","form_type":"4"}},{"id":2571429,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2021-09-14T20:14:23.000Z","date":"2021-09-10","kind":"exercise","acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":1.71,"exercise_date":"2013-06-30","expiration_date":"2023-05-31","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001127602-21-025252","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221025252/form4.xml","form_type":"4"}},{"id":2571428,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-09-14T20:14:23.000Z","date":"2021-09-10","kind":"sale","acquired":false,"shares":74000,"price":15.09,"value":1116660.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $14.87 to $15.31. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001127602-21-025252","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221025252/form4.xml","form_type":"4"}},{"id":2571427,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-09-14T20:14:23.000Z","date":"2021-09-10","kind":"exercise","acquired":true,"shares":30000,"price":2.91,"value":87300.0,"ownership":{"direct":true},"balance_after":74000,"source":{"system":"sec-edgar","filing":"0001127602-21-025252","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221025252/form4.xml","form_type":"4"}},{"id":2571426,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-09-14T20:14:23.000Z","date":"2021-09-10","kind":"exercise","acquired":true,"shares":30000,"price":3.22,"value":96600.0,"ownership":{"direct":true},"balance_after":44000,"source":{"system":"sec-edgar","filing":"0001127602-21-025252","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221025252/form4.xml","form_type":"4"}},{"id":2571425,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-09-14T20:14:23.000Z","date":"2021-09-10","kind":"exercise","acquired":true,"shares":11000,"price":1.71,"value":18810.0,"ownership":{"direct":true},"balance_after":14000,"source":{"system":"sec-edgar","filing":"0001127602-21-025252","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221025252/form4.xml","form_type":"4"}},{"id":2631106,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Non-Qualified Stock Option","published_at":"2021-07-19T20:39:54.000Z","date":"2021-07-15","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 1/8 per month for a period of 8 months, beginning on October 10, 2011."}],"balance_after":5000,"derivative":{"exercise_price":2.63,"expiration_date":"2021-10-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-21-022226","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221022226/form4.xml","form_type":"4"}},{"id":2631105,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-07-19T20:39:54.000Z","date":"2021-07-15","kind":"sale","acquired":false,"shares":5000,"price":15.69,"value":78450.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.46 to $16.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001127602-21-022226","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221022226/form4.xml","form_type":"4"}},{"id":2631104,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-07-19T20:39:54.000Z","date":"2021-07-15","kind":"exercise","acquired":true,"shares":5000,"price":2.63,"value":13150.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001127602-21-022226","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221022226/form4.xml","form_type":"4"}},{"id":2694224,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2021-05-27T20:11:48.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan."}],"balance_after":40000,"derivative":{"exercise_price":13.28,"exercise_date":"2022-05-25","expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001127602-21-018171","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221018171/form4.xml","form_type":"4"}},{"id":2696094,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Non-Qualified Stock Option","published_at":"2021-05-26T20:12:11.000Z","date":"2021-05-24","kind":"exercise","acquired":false,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested 1/8 per month for a period of 8 months, beginning on October 10, 2011."}],"balance_after":10000,"derivative":{"exercise_price":2.63,"expiration_date":"2021-10-10","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0001127602-21-018061","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221018061/form4.xml","form_type":"4"}},{"id":2696093,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-05-26T20:12:11.000Z","date":"2021-05-24","kind":"sale","acquired":false,"shares":6667,"price":13.9,"value":92671.3,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $13.77 to $14.11. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001127602-21-018061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221018061/form4.xml","form_type":"4"}},{"id":2696092,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-05-26T20:12:11.000Z","date":"2021-05-24","kind":"exercise","acquired":true,"shares":6667,"price":2.63,"value":17534.21,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021."}],"balance_after":9667,"source":{"system":"sec-edgar","filing":"0001127602-21-018061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221018061/form4.xml","form_type":"4"}},{"id":2717373,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-05-12T21:02:04.000Z","date":"2021-05-10","kind":"sale","acquired":false,"shares":7000,"price":12.7,"value":88900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.69 to $12.72. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001127602-21-016433","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760221016433/form4.xml","form_type":"4"}},{"id":3149736,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2020-05-14T20:14:54.000Z","date":"2020-05-12","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan."}],"balance_after":40000,"derivative":{"exercise_price":5.41,"exercise_date":"2021-05-12","expiration_date":"2030-05-12","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001127602-20-016548","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760220016548/form4.xml","form_type":"4"}},{"id":3265042,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Stock Options","published_at":"2020-02-19T17:07:09.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":8764,"price":1.16,"value":10166.24,"ownership":{"direct":true},"balance_after":8764,"derivative":{"exercise_price":1.16,"exercise_date":"2020-02-14","expiration_date":"2030-02-13","underlying":"Common Stock","underlying_shares":8764},"source":{"system":"sec-edgar","filing":"0001214659-20-001606","document":"marketforms-47805.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/819050/000121465920001606/marketforms-47805.xml","form_type":"4"}},{"id":3265041,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Units","published_at":"2020-02-19T17:07:09.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":2167,"price":1.16,"value":2513.72,"ownership":{"direct":true},"balance_after":2167,"derivative":{"exercise_price":1.16,"exercise_date":"2020-02-14","expiration_date":"2030-02-13","underlying":"Common Stock","underlying_shares":2167},"source":{"system":"sec-edgar","filing":"0001214659-20-001606","document":"marketforms-47805.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/819050/000121465920001606/marketforms-47805.xml","form_type":"4"}},{"id":3506755,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2019-05-31T20:10:42.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan."}],"balance_after":30000,"derivative":{"exercise_price":2.91,"exercise_date":"2020-05-29","expiration_date":"2029-05-29","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001127602-19-020298","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760219020298/form4.xml","form_type":"4"}},{"id":3836286,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Comm. Officer"}}],"security":"Common Stock","published_at":"2018-08-22T22:46:58.000Z","date":"2018-08-21","kind":"sale","acquired":false,"shares":8000,"price":14.105,"value":112840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.9100 to $14.1950, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4."}],"balance_after":285479,"source":{"system":"sec-edgar","filing":"0001567619-18-001672","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000156761918001672/doc1.xml","form_type":"4"}},{"id":3836285,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Comm. Officer"}}],"security":"Common Stock","published_at":"2018-08-22T22:46:58.000Z","date":"2018-08-20","kind":"tax_withholding","acquired":false,"shares":5680,"price":14.08,"value":79974.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants."}],"balance_after":293479,"source":{"system":"sec-edgar","filing":"0001567619-18-001672","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000156761918001672/doc1.xml","form_type":"4"}},{"id":3885601,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2018-06-22T13:25:57.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests 1/12th per month over twelve months beginning July 20, 2018."}],"balance_after":30000,"derivative":{"exercise_price":6.09,"exercise_date":"2018-07-20","expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001127602-18-021724","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760218021724/form4.xml","form_type":"4"}},{"id":3922533,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Comm. Officer"}}],"security":"Common Stock","published_at":"2018-05-22T23:52:21.000Z","date":"2018-05-21","kind":"sale","acquired":false,"shares":8000,"price":14.4003,"value":115202.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was effected for tax planning purposes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.31 to $14.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 1,924 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on May 15, 2018."}],"balance_after":299159,"source":{"system":"sec-edgar","filing":"0001179110-18-007382","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000117911018007382/edgar.xml","form_type":"4"}},{"id":3922532,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Comm. Officer"}}],"security":"Common Stock","published_at":"2018-05-22T23:52:21.000Z","date":"2018-05-20","kind":"tax_withholding","acquired":false,"shares":4682,"price":14.59,"value":68310.38,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants."}],"balance_after":305235,"source":{"system":"sec-edgar","filing":"0001179110-18-007382","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000117911018007382/edgar.xml","form_type":"4"}},{"id":4012022,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Comm. Officer"}}],"security":"Common Stock","published_at":"2018-03-06T21:14:04.000Z","date":"2018-03-02","kind":"grant","acquired":true,"shares":74444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 24,814 shares of common stock granted pursuant to a time-based restricted stock award (RSA). Twenty-five percent of the shares subject to the RSA shall vest on February 20, 2019, and 6.25% of the shares subject to the RSA shall vest quarterly thereafter on the Issuer's standard vesting dates until February 20, 2022, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes shares of common stock granted pursuant to a performance-based restricted stock award (PSA). The shares vest pursuant to the PSA over a three-year period upon, and subject to a formula related to, the Issuer's achievement of certain levels of relative total shareholder return (TSR). The \"target\" number of shares that may vest is 24,815, but the actual number of shares that may vest will range from 0 to 49,630 shares based on the Issuer's relative TSR over the performance period. Subject to achievement of the performance-based vesting conditions, the shares eligible to vest based on achievement will vest on February 20, 2021 provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date."}],"balance_after":309917,"source":{"system":"sec-edgar","filing":"0001179110-18-003602","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000117911018003602/edgar.xml","form_type":"4"}},{"id":4041177,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Comm. Officer"}}],"security":"Common Stock","published_at":"2018-02-22T21:23:28.000Z","date":"2018-02-21","kind":"sale","acquired":false,"shares":8000,"price":16.5125,"value":132100.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was effected for tax planning purposes pursuant to the Reporting Person's Rule 10b5-1 Trading Plan dated September 20, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.31 to $16.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 322 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on November 15, 2017."}],"balance_after":235473,"source":{"system":"sec-edgar","filing":"0001179110-18-002588","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000117911018002588/edgar.xml","form_type":"4"}},{"id":4041176,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Comm. Officer"}}],"security":"Common Stock","published_at":"2018-02-22T21:23:28.000Z","date":"2018-02-20","kind":"tax_withholding","acquired":false,"shares":15500,"price":16.44,"value":254820.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants."}],"balance_after":243473,"source":{"system":"sec-edgar","filing":"0001179110-18-002588","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000117911018002588/edgar.xml","form_type":"4"}},{"id":4153133,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Comm. Officer"}}],"security":"Common Stock","published_at":"2017-11-22T21:52:58.000Z","date":"2017-11-21","kind":"sale","acquired":false,"shares":5215,"price":13.2589,"value":69145.1635,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was effected for tax planning purposes pursuant to the Reporting Person's Rule 10b5-1 Trading Plan dated September 20, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.21 to $13.395, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4."}],"balance_after":258651,"source":{"system":"sec-edgar","filing":"0001179110-17-014574","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000117911017014574/edgar.xml","form_type":"4"}},{"id":4153132,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Comm. Officer"}}],"security":"Common Stock","published_at":"2017-11-22T21:52:58.000Z","date":"2017-11-20","kind":"tax_withholding","acquired":false,"shares":3358,"price":13.17,"value":44224.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants."}],"balance_after":263866,"source":{"system":"sec-edgar","filing":"0001179110-17-014574","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000117911017014574/edgar.xml","form_type":"4"}},{"id":4227793,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Comm. Officer"}}],"security":"Common Stock","published_at":"2017-08-22T20:38:43.000Z","date":"2017-08-20","kind":"tax_withholding","acquired":false,"shares":2886,"price":12.28,"value":35440.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were withheld by the Company to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards."}],"balance_after":267224,"source":{"system":"sec-edgar","filing":"0001179110-17-011732","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000117911017011732/edgar.xml","form_type":"4"}},{"id":4305567,"issuer":{"id":315,"kind":"organization","name":"BIOCRYST PHARMACEUTICALS INC","symbol":"BCRX"},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":true}}],"security":"Automatic Stock Option Grant","published_at":"2017-05-25T15:37:17.000Z","date":"2017-05-24","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests 1/12th per month over twelve months beginning June 24, 2017."}],"balance_after":30000,"derivative":{"exercise_price":5.13,"exercise_date":"2017-06-24","expiration_date":"2027-05-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001127602-17-019325","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882796/000112760217019325/form4.xml","form_type":"4"}},{"id":4308621,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Comm. Officer"}}],"security":"Common Stock","published_at":"2017-05-23T20:15:33.000Z","date":"2017-05-20","kind":"tax_withholding","acquired":false,"shares":2228,"price":11.86,"value":26424.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,500 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on May 15, 2017."}],"balance_after":270110,"source":{"system":"sec-edgar","filing":"0001179110-17-007831","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000117911017007831/edgar.xml","form_type":"4"}},{"id":4432718,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Comm. Officer"}}],"security":"Common Stock","published_at":"2017-02-22T21:31:12.000Z","date":"2017-02-20","kind":"tax_withholding","acquired":false,"shares":5355,"price":12.04,"value":64474.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards."}],"balance_after":269838,"source":{"system":"sec-edgar","filing":"0001179110-17-002899","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000117911017002899/edgar.xml","form_type":"4"}},{"id":4486933,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Comm. Officer"}}],"security":"Common Stock","published_at":"2017-01-20T01:26:36.000Z","date":"2017-01-17","kind":"grant","acquired":true,"shares":106718,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 53,358 shares of common stock granted pursuant to a time-based restricted stock award (RSA).  Twenty-five percent of the shares subject to the RSA shall vest on February 20, 2018, and 6.25% of the shares subject to the RSA shall vest quarterly thereafter on the Issuer's standard vesting dates until February 20, 2021, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes shares of common stock granted pursuant to a performance-based restricted stock award (PSA).  The shares vest pursuant to the PSA over a two-year and three-year performance period upon, and subject to a formula related to, the Issuer's achievement of certain levels of relative total shareholder return (TSR).  The \"target\" number of shares that may vest is 26,680, but the actual number of shares that may vest will range from 0 to 53,360 shares based on the Issuer's relative TSR over the performance periods.  Subject to achievement of the performance-based vesting conditions, (i) two-thirds of the shares eligible to vest based on achievement for the two-year performance period will vest on February 20, 2019 and the remaining one-third of such shares will vest on February 20, 2020 and (ii) the share eligible to vest based on achievement for the three-year performance period will vest on February 20, 2020, in each case, (continued in Footnote 3)"},{"field":"shares","element":"transactionShares","label":"F3","text":"(continued from Footnote 2) provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date."}],"balance_after":275193,"source":{"system":"sec-edgar","filing":"0001179110-17-001087","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000117911017001087/edgar.xml","form_type":"4"}},{"id":4545580,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":89909,"kind":"person","name":"ABERCROMBIE GEORGE B","position":1,"cik":"0001485939","reported_name":"ABERCROMBIE GEORGE B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & Chief Comm. Officer"}}],"security":"Common Stock","published_at":"2016-11-22T22:39:26.000Z","date":"2016-11-20","kind":"tax_withholding","acquired":false,"shares":1273,"price":10.91,"value":13888.43,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity awards."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 285 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on November 15, 2016."}],"balance_after":168475,"source":{"system":"sec-edgar","filing":"0001179110-16-031970","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000117911016031970/edgar.xml","form_type":"4"}}]}